$ENTX
Entera Bio Ltd. Ordinary Shares
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
$2.56
▲+2.60%+$0.065
Subscriptions are live. Early access $24.99/mo, or start with 5 free premium days.
Plans & pricingDonateEntera Bio Ltd. Ordinary Shares
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
Why is ENTX up today? It is at $2.56 (+2.60%), and our scanner flagged it 31 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment ENTX spikes, and full due diligence on ENTX — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $ENTX 31 times in the last 30 days. Create a free account to track $ENTX, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
ENTX is one of today's most active names, trading on unusually heavy volume (live price and day move above). Our scanner has fired 2 unusual-volume and momentum alerts on ENTX today, peaking at 141.7x its normal volume.
Likely catalystAppoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial ExpertiseReported Commercial Operations at Gilead Sciences, Inc., where she led an organization of approximately 2,500 employees responsible for $22 billionReported led commercial activities and supporting functions across Amgen's therapeutic areas, representing approximately 80% of Amgen's, from the latest SEC filing. Read it →A share sale has already completed, so that supply is out there. Size not stated in the filing.
Some filings did not state a size, so these are floors.
Recent share offering + active shelf on file — the company raised capital and can raise more
Sources: float & market cap via Polygon · short interest via FINRA · borrow & shortability via Alpaca · SSR from Reg SHO 201 · filings & dilution via SEC EDGAR · analysts via Nasdaq.
Auto-generated from public data for research and education. Not investment advice.
From the trading subreddits (WallStreetBets, r/stocks and more). Retail chatter, not a signal. Do your own research.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Germano Geno J Director | Acquired (grant/award) | +25K 0.01% of company | added 63% | 65K | n/a | Aug 7, 26 |
Ellis Sean Director | Acquired (grant/award) | +20K 0.01% of company | added 11% | 208K | n/a | Aug 7, 26 |
Taitel Haya Director | Acquired (grant/award) | +21K 0.01% of company | added 21% | 119K | n/a | Aug 7, 26 |
Malca Yonatan Director | Acquired (grant/award) | +23K 0.01% of company | added 29% | 100K | n/a | Aug 7, 26 |
Rubin Steven D Director | Acquired (grant/award) | +19K 0.01% of company | added 100% | 34K | n/a | Aug 7, 26 |
Toledano Miranda Jayne Officer | Acquired (grant/award) | +421K 0.2% of company | added 99% | 847K | n/a | Jul 14, 26 |
Burshtein Gregory Officer | Acquired (grant/award) | +88K 0.05% of company | added 86% | 189K | n/a | May 7, 26 |
Yaacov-Garbeli Dana Officer | Acquired (grant/award) | +58K 0.03% of company | added 52% | 171K | n/a | May 7, 26 |
Galitzer Hillel Officer | Acquired (grant/award) | +73K 0.04% of company | added 81% | 164K | n/a | May 7, 26 |
Germano Geno J Director | Bought (open market) | +20K 0.01% of company | added 100% | 40K | $26K at $1.30 | Mar 9, 26 |
Ellis Sean Director | Bought (open market) | +10K | added 5.6% | 188K | $12K at $1.23 | Mar 5, 26 |
Rubin Steven D Director | Bought (open market) | +5K | added 50% | 15K | $7K at $1.49 | Feb 12, 26 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
The tickers our scanner is lighting up most over the last 48 hours.
Comparable names in biological products, (no diagnostic substances), closest in size first.
ENTX is one of today's most active names, trading on unusually heavy volume (live price and day move above). Our scanner has fired 2 unusual-volume and momentum alerts on ENTX today, peaking at 141.7x its normal volume.
ENTX last traded at $2.56, up 2.60% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Entera Bio Ltd. Ordinary Shares (ENTX) is next expected to report earnings on Friday, November 13, 2026, about 35 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
The ENTX Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged ENTX 31 times in the last 30 days.
ENTX (Entera Bio Ltd. Ordinary Shares) trades on XNAS, with a market cap of about $433M in the Biological Products, (No Diagnostic Substances) sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge ENTX for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$ENTX discussion
Sign in to ask a question or join the discussion.